Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
NCT ID: NCT00754104
Last Updated: 2011-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
NCT00586092
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
NCT01154426
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
NCT01063816
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
NCT05532696
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
NCT03099174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ABT-869
0.25 mg/kg. daily.
Tarceva
150mg, daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-869
0.25 mg/kg. daily.
Tarceva
150mg, daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have an ECOG Score of 0-2.
* Adequate organ function.
Exclusion Criteria
* Subject has untreated brain or meningeal metastases.
* History of greater than 10% weight loss.
* Has clinically relevant hemoptysis.
* Subject has proteinuria CTC grade \> 1.
* Must not have had radiation therapy or major surgery within 21 days of study day 1.
* The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (DBP) \> 100 mmHg or systolic blood pressure (SBP) \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention.
* The subject has a documented left ventricular ejection fraction (LVEF) \< 50%.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abbott
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-371
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.